EMCIP
XBI icon

Ewing Morris & Co Investment Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ewing Morris & Co Investment Partners’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,730
Closed -$337K – 100
2025
Q4 		$337K Buy
+2,730
New +$313K 0.15% 81

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ewing Morris & Co Investment Partners's XBI Position: Q1 2026 in Review

Ewing Morris & Co Investment Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 2,730 shares — an estimated $337K sold.

Ewing Morris & Co Investment Partners first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $337K in Q4 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Ewing Morris & Co Investment Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Ewing Morris & Co Investment Partners sold 2,730 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $337K.
  • Ewing Morris & Co Investment Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
  • Ewing Morris & Co Investment Partners's State Street SPDR S&P Biotech ETF position peaked at $337K in Q4 2025.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Ewing Morris & Co Investment Partners's 13F filing for Q1 2026, filed 11 May 2026.